JP2011500003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500003A5 JP2011500003A5 JP2010527594A JP2010527594A JP2011500003A5 JP 2011500003 A5 JP2011500003 A5 JP 2011500003A5 JP 2010527594 A JP2010527594 A JP 2010527594A JP 2010527594 A JP2010527594 A JP 2010527594A JP 2011500003 A5 JP2011500003 A5 JP 2011500003A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- compound
- compound according
- moiety
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 210000004072 Lung Anatomy 0.000 claims 3
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 3
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010049460 Abasia Diseases 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 101700013799 CASP2 Proteins 0.000 claims 2
- 102100019268 CASP2 Human genes 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- 210000003734 Kidney Anatomy 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 206010038436 Renal failure acute Diseases 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 101710032514 ACTI Proteins 0.000 claims 1
- -1 ATF3 Proteins 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 102100005377 BMP2 Human genes 0.000 claims 1
- 101700000123 BMP2 Proteins 0.000 claims 1
- 101700007682 BNIP3 Proteins 0.000 claims 1
- 102100007320 BNIP3 Human genes 0.000 claims 1
- 102100007817 C1QBP Human genes 0.000 claims 1
- 101700015250 C1QBP Proteins 0.000 claims 1
- 102100020540 CCN2 Human genes 0.000 claims 1
- 101700026049 CCN2 Proteins 0.000 claims 1
- 102100003279 CD38 Human genes 0.000 claims 1
- 101700044948 CD38 Proteins 0.000 claims 1
- 101710008837 CYBA Proteins 0.000 claims 1
- 102100014445 CYBA Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100016632 DUOX1 Human genes 0.000 claims 1
- 101700087024 DUOX1 Proteins 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N Deoxyribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 102100008407 GJA1 Human genes 0.000 claims 1
- 101710007424 GJA1 Proteins 0.000 claims 1
- 102100007245 GSK3B Human genes 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102100001309 HRK Human genes 0.000 claims 1
- 101700021651 HRK Proteins 0.000 claims 1
- 208000004559 Hearing Loss Diseases 0.000 claims 1
- 206010011879 Hearing loss Diseases 0.000 claims 1
- 210000002216 Heart Anatomy 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 102100005531 MAPK8 Human genes 0.000 claims 1
- 101710029924 MAPK8 Proteins 0.000 claims 1
- 102000003841 Mitogen-Activated Protein Kinase 14 Human genes 0.000 claims 1
- 108090000139 Mitogen-Activated Protein Kinase 14 Proteins 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 102100011850 NOX3 Human genes 0.000 claims 1
- 101700081499 NOX3 Proteins 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 102100010180 P2RX7 Human genes 0.000 claims 1
- 101700064615 P2RX7 Proteins 0.000 claims 1
- 102100005222 PARG Human genes 0.000 claims 1
- 101700085610 PARG Proteins 0.000 claims 1
- 102100016461 PIDD1 Human genes 0.000 claims 1
- 101700026154 PIDD1 Proteins 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 101700023645 RAC1 Proteins 0.000 claims 1
- 102100002253 RAC1 Human genes 0.000 claims 1
- 101700025113 RAC3 Proteins 0.000 claims 1
- 101700020165 RHOA Proteins 0.000 claims 1
- 102100004989 RHOA Human genes 0.000 claims 1
- 101710002310 RNASE1 Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 229920001914 Ribonucleotide Polymers 0.000 claims 1
- 102100008951 SGPP1 Human genes 0.000 claims 1
- 108060007846 SPP2 Proteins 0.000 claims 1
- 101710009476 STEAP4 Proteins 0.000 claims 1
- 102100006454 STEAP4 Human genes 0.000 claims 1
- 229920000972 Sense strand Polymers 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 102100012637 TP53BP2 Human genes 0.000 claims 1
- 101710009064 TP53BP2 Proteins 0.000 claims 1
- 108060008546 TRPM2 Proteins 0.000 claims 1
- 102000003615 TRPM2 Human genes 0.000 claims 1
- 108060008723 TYROBP Proteins 0.000 claims 1
- 102100008188 TYROBP Human genes 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000010927 mucositis Diseases 0.000 claims 1
- 230000002887 neurotoxic Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000241 respiratory Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
Claims (13)
- 以下に記載の構造を有する化合物:
5’ (N)x−Z 3’(アンチセンス鎖)
3’ Z’−(N’)y−z’’ 5’(センス鎖)
[式中、NおよびN’のそれぞれは、非修飾もしくは修飾であり得るリボヌクレオチド、または非慣用部分であり;
(N)xおよび(N’)yのそれぞれは、それぞれの連続するNまたはN’が共有結合によって次のNまたはN’と結合しているオリゴヌクレオチドであり;
ZおよびZ’は、存在しても存在しなくてもよいが、存在する場合は、独立して、それが存在する鎖の3’末端で共有結合した1〜5個の連続したヌクレオチドであり;
z’’は、(N’)yの5’末端で共有結合したキャップ部分であり;
x=y=19であり;
(N)xは、3’末端を起点として少なくとも5個の交互に現れる修飾リボヌクレオチドかつ合計で少なくとも9個の修飾リボヌクレオチドを含み、それぞれの修飾リボヌクレオチドはその糖上に2’−O−メチルを有し、それぞれの残りのNは非修飾リボヌクレオチド又は非慣用部分であり;
(N’)y中にあって、15、16、17、又は、18位に存在するN’の少なくとも1つは、非慣用部分であり、当該非慣用部分は、脱塩基リボース部分、脱塩基デオキシリボース部分、修飾または非修飾のデオキシリボヌクレオチド、鏡像異性体ヌクレオチド、又は2’−5’ヌクレオチド間リン酸結合によって隣接ヌクレオチドと結合しているヌクレオチドであり;
(N)xの配列は、(N’)yの配列に対して実質的に相補的であり;
(N’)yの配列は、標的遺伝子によってコードされているmRNAの配列と実質的に同一である]。 - (N’)yにおける少なくとも1つの非慣用部分が鏡像異性体ヌクレオチドである、請求項1に記載の化合物。
- 鏡像異性体ヌクレオチドが位置17、位置18、または位置17と18に存在する、請求項2に記載の化合物。
- 少なくとも1つのN’がLNAである、請求項1に記載の化合物。
- 請求項1に記載の化合物と、製薬上許容される担体とを含む薬剤組成物。
- 疾病または疾患の予防または治療を必要とする対象において、疾患または疾病の発生または重篤度を治療または予防するのに用いられる請求項5に記載の薬剤組成物であって、前記疾患もしくは前記疾患および/またはそれに関連する症状が、聴覚損失、急性腎不全(ARF)、緑内障、急性呼吸窮迫症候群(ARDS)および他の急性の肺や呼吸器の傷害、肺移植後の虚血再灌流傷害、前部虚血性視神経症を含めた眼球虚血状態、肺、肝臓、心臓、膵臓、および腎臓の移植を含めた臓器移植(臓器移植後臓器機能障害(DGF)を含む)、腎臓および神経毒性、脊髄傷害、褥瘡、加齢黄斑変性症(AMD)、ドライアイ症候群、虚血性視神経症(ION)、口腔粘膜炎又は慢性閉塞性肺疾患(COPD)から選択される薬剤組成物。
- 請求項1に記載の化合物であって、ZおよびZ’は、存在しないことを特徴とする化合物。
- 請求項1に記載の化合物であって、前記標的遺伝子が、TP53BP2,LRDD,CYBA,ATF3,CASP2,NOX3,HRK,C1QBP,BNIP3,MAPK8,MAPK14,RAC1,GSK3B,P2RX7,TRPM2,PARG,CD38,STEAP4,BMP2,GJA1,TYROBP,CTGF,SPP1,RHOA,又はDUOX1(配列番号1−41又は46−48)から選択されることを特徴とする化合物。
- 請求項3又は8に記載の化合物であって、(N)xが、位置2,4,6,8,11,13,15,17,19に2’O−Me糖修飾リボヌクレオチドを含み、それぞれの残りのNは、非修飾リボヌクレオチドであることを特徴とする化合物。
- 請求項8に記載の化合物であって、(N’)yの配列が、CASP2標的遺伝子によってコードされるmRNAの配列(配列番号10又は11)に実質的に同一であることを特徴とする化合物。
- 請求項10に記載の化合物であって、(N)xの配列が、配列番号134,136,138,140,87154,87156,87158,87160,87162,87164,87166,87168,87170,87172,87174,87176,又は87178のいずれかに規定される配列を含むことを特徴とする化合物。
- 請求項10に記載の化合物であって、(N’)yの配列が、配列番号133,135,137,139,87153,87155,87157,87159,87161,87163,87165,87167,87169,87171,87173,87175,又は87177のいずれかに規定される配列を含むことを特徴とする化合物。
- 請求項10に記載の化合物であって、(N)xの配列が配列番号140を含み、(N’)yの配列が、配列番号139を含むことを特徴とする化合物。
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99757607P | 2007-10-03 | 2007-10-03 | |
US60/997,576 | 2007-10-03 | ||
US66407P | 2007-10-25 | 2007-10-25 | |
US61/000,664 | 2007-10-25 | ||
US353507P | 2007-11-15 | 2007-11-15 | |
US61/003,535 | 2007-11-15 | ||
US1004008P | 2008-01-04 | 2008-01-04 | |
US61/010,040 | 2008-01-04 | ||
US12851908P | 2008-05-22 | 2008-05-22 | |
US61/128,519 | 2008-05-22 | ||
US13463808P | 2008-07-10 | 2008-07-10 | |
US61/134,638 | 2008-07-10 | ||
US18903508P | 2008-08-15 | 2008-08-15 | |
US61/189,035 | 2008-08-15 | ||
PCT/IL2008/001197 WO2009044392A2 (en) | 2007-10-03 | 2008-09-04 | Novel sirna structures |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014125717A Division JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規siRNA構造 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011500003A JP2011500003A (ja) | 2011-01-06 |
JP2011500003A5 true JP2011500003A5 (ja) | 2011-10-27 |
JP5646997B2 JP5646997B2 (ja) | 2014-12-24 |
Family
ID=40526792
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010527594A Expired - Fee Related JP5646997B2 (ja) | 2007-10-03 | 2008-09-04 | 新規siRNA構造 |
JP2014125717A Pending JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規siRNA構造 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014125717A Pending JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規siRNA構造 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8614309B2 (ja) |
EP (1) | EP2231168A4 (ja) |
JP (2) | JP5646997B2 (ja) |
KR (1) | KR20100085951A (ja) |
CN (2) | CN101815521B (ja) |
AU (1) | AU2008306455C1 (ja) |
BR (1) | BRPI0817605A2 (ja) |
CA (1) | CA2701845A1 (ja) |
RU (1) | RU2487716C2 (ja) |
WO (1) | WO2009044392A2 (ja) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE350473T2 (de) | 2002-08-05 | 2007-01-15 | Atugen Ag | Weitere neue formen von interferierende rns moleküle |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
JP5646997B2 (ja) | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 新規siRNA構造 |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
WO2009074990A2 (en) * | 2007-12-12 | 2009-06-18 | Quark Pharmaceuticals, Inc. | Rtp801l sirna compounds and methods of use thereof |
WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
CN104975020B (zh) | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | 经修饰的RNAi多核苷酸及其用途 |
JP2011517404A (ja) * | 2008-03-20 | 2011-06-09 | クォーク・ファーマシューティカルズ・インク | RTP801を阻害するための新規なsiRNA化合物 |
US8278287B2 (en) * | 2008-04-15 | 2012-10-02 | Quark Pharmaceuticals Inc. | siRNA compounds for inhibiting NRF2 |
JP5524189B2 (ja) * | 2008-06-06 | 2014-06-18 | クォーク ファーマシューティカルズ インコーポレーティッド | 耳障害治療のための組成物および方法 |
TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
CA2738957A1 (en) | 2008-10-22 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
WO2010046889A1 (en) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for delivery of sirna to bone marrow cells and uses thereof |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
CN104861066B (zh) | 2009-03-23 | 2018-05-08 | 夸克制药公司 | 治疗癌症和纤维化疾病的化合物组合物和方法 |
EP3276004B1 (en) * | 2009-06-08 | 2020-03-18 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
EP2264169A1 (en) * | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
WO2011057171A1 (en) | 2009-11-08 | 2011-05-12 | Quark Pharmaceuticals, Inc. | METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM |
KR20120102630A (ko) * | 2009-11-26 | 2012-09-18 | 쿠아크 파마수티칼스 인코퍼레이티드 | 말단 치환체를 포함하는 에스아이 알엔에이 화합물 |
EP2509991B1 (en) | 2009-12-09 | 2015-11-11 | Nitto Denko Corporation | Modulation of hsp47 expression |
US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
AU2011232365A1 (en) | 2010-03-24 | 2012-10-25 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
AU2011270896B9 (en) | 2010-06-24 | 2015-05-07 | Quark Pharmaceuticals, Inc. | Double stranded RNA compounds to RhoA and use thereof |
EP3372684B1 (en) * | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
GB201015974D0 (en) * | 2010-09-23 | 2010-11-03 | Univ Warwick | Sirna |
KR101328568B1 (ko) | 2010-10-22 | 2013-11-13 | 성균관대학교산학협력단 | Rna 간섭을 유도하는 핵산 분자 및 그 용도 |
EP2649181B1 (en) * | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
CN103562387A (zh) | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Toll样受体途径的寡核苷酸调剂 |
BR112014010769B1 (pt) | 2011-11-03 | 2021-08-03 | Quark Pharmaceuticals, Inc | Uso de um composto de rna de fita dupla para preparar um medicamento para tratar doença de ménière |
US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
SG11201403756PA (en) | 2012-01-01 | 2014-11-27 | Qbi Entpr Ltd | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
CN104053776A (zh) * | 2012-01-04 | 2014-09-17 | 夸克制药公司 | Casp2的双链rna化合物及其用途 |
CN102743763B (zh) * | 2012-04-11 | 2013-11-06 | 中山大学中山眼科中心 | 一种治疗青光眼的药物 |
CN102703508A (zh) * | 2012-05-18 | 2012-10-03 | 边红 | 靶向GSK3β基因RNA干扰重组慢病毒载体及其构建、筛选方法 |
EP3514236A1 (en) * | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
WO2014043292A1 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
EP2895607B1 (en) | 2012-09-12 | 2021-05-05 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
CN102911940B (zh) * | 2012-10-11 | 2014-02-05 | 江苏省疾病预防控制中心 | 特异性抑制nk细胞受体kir3dl1的小核酸干扰分子及其应用 |
US9896688B2 (en) | 2013-02-22 | 2018-02-20 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage |
EP3027223A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
EP2865758A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
WO2015084897A2 (en) | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
DK3149172T3 (en) * | 2014-05-29 | 2018-08-20 | Quark Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE PREVENTION OF ISKEMIC REPERFUSION LESSON IN BODIES |
US20170106047A1 (en) * | 2014-06-12 | 2017-04-20 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
WO2017007813A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
MA44908A (fr) | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
CN108699556B (zh) | 2015-11-16 | 2023-02-17 | 奥利克斯医药有限公司 | 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性 |
JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ,インコーポレーテッド | IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療 |
EP3411481A4 (en) | 2016-02-02 | 2020-02-26 | Olix Pharmaceuticals, Inc. | TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES |
EP3420087B1 (en) * | 2016-02-23 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Peptide-based methods for treating neurological injury |
US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
AU2017312116A1 (en) | 2016-08-17 | 2019-03-07 | Solstice Biologics, Ltd. | Polynucleotide constructs |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
JP7072748B2 (ja) * | 2016-12-28 | 2022-05-23 | 国立大学法人神戸大学 | アルポート症候群治療薬 |
EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
EP3645546A4 (en) | 2017-06-30 | 2021-12-01 | Solstice Biologics, Ltd. | CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE |
EP3790557A4 (en) * | 2018-05-07 | 2022-03-02 | Alnylam Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR ENHANCING STRAND DISTORTION |
CN114981430A (zh) * | 2019-08-27 | 2022-08-30 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中的c3表达的核酸 |
KR20210063137A (ko) * | 2019-11-22 | 2021-06-01 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
WO1992001704A1 (fr) | 1990-07-26 | 1992-02-06 | Koichi Shudo | Oligodesoxyribonucleotides |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
WO1995000160A1 (en) | 1993-06-24 | 1995-01-05 | The General Hospital Corporation | Programmed cell death genes and proteins |
ES2186690T3 (es) | 1993-09-02 | 2003-05-16 | Ribozyme Pharm Inc | Acido nucleico enzimatico que contiene no-nucleotidos. |
US5858678A (en) | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
EP0799892A3 (en) | 1996-04-05 | 1998-08-12 | Takeda Chemical Industries, Ltd. | Calpain, its production and use |
US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
US5753789A (en) | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
US5929042A (en) | 1997-03-03 | 1999-07-27 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
US7223856B2 (en) | 1997-03-03 | 2007-05-29 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
AU9016898A (en) | 1997-08-07 | 1999-03-01 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Methods and compositions for treatment of restenosis |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
IL134298A0 (en) | 1997-08-21 | 2001-04-30 | Quark Biotech Inc | Hypoxia-regulating genes |
EP2253639A1 (en) | 1997-09-12 | 2010-11-24 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
US20030125277A1 (en) | 2001-11-08 | 2003-07-03 | Isis Pharmaceuticals Inc. | Antisense modulation of activating transcription factor 3 expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
WO2000044409A1 (en) | 1999-01-27 | 2000-08-03 | University College London | Formulations comprising antisense nucleotides to connexins |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
AU3369900A (en) | 1999-02-19 | 2000-09-04 | General Hospital Corporation, The | Gene silencing |
US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
US6140124A (en) | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
AU781598B2 (en) | 1999-04-21 | 2005-06-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
AU6974900A (en) | 1999-09-07 | 2001-04-10 | University Health Network | A p53-induced protein with a death domain that can promote apoptosis |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
EP1226252A2 (en) | 1999-11-02 | 2002-07-31 | Chiron Corporation | DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
US6323029B1 (en) | 2000-01-19 | 2001-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glycogen synthase kinase 3 beta expression |
WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
WO2002024720A1 (en) | 2000-09-20 | 2002-03-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 2 expression |
FR2815541B1 (fr) | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
WO2003004602A2 (en) * | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
GB0116955D0 (en) | 2001-07-11 | 2001-09-05 | Syngenta Ltd | Weed control process |
ES2629615T3 (es) | 2001-10-26 | 2017-08-11 | Noxxon Pharma Ag | Ácido L-nucleico modificado |
WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
ES2401326T3 (es) | 2001-11-21 | 2013-04-18 | Astellas Pharma Inc. | Procedimiento para inhibir la expresión génica |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
JP2006500910A (ja) | 2002-04-18 | 2006-01-12 | アキュイティ ファーマシューティカルズ、インク. | Cnsと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法 |
AU2003256636A1 (en) | 2002-07-22 | 2004-02-09 | University Of Miami | Preventing ischemia-induced cell damage |
AU2003268023A1 (en) | 2002-07-23 | 2004-02-09 | Incyte Corporation | Protein modification and maintenance molecules |
ATE350473T2 (de) | 2002-08-05 | 2007-01-15 | Atugen Ag | Weitere neue formen von interferierende rns moleküle |
US20040142865A1 (en) | 2002-10-02 | 2004-07-22 | Weber Georg F. | Osteopontin-based cancer therapies |
AU2003304386A1 (en) | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
AU2002952550A0 (en) | 2002-11-08 | 2002-11-21 | The University Of Queensland | Modulating TNFalpha Secretion |
ATE517992T1 (de) | 2002-11-14 | 2011-08-15 | Dharmacon Inc | Funktionelle und hyperfunktionelle sirna |
US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
DK1606406T4 (da) | 2003-03-21 | 2013-12-16 | Santaris Pharma As | Short Interfering RNA (siRNA) Analogues |
WO2004103389A2 (en) | 2003-05-22 | 2004-12-02 | Theraptosis Sa | Means for preventing and treating cellular death and their biological applications |
EP3502252B1 (en) | 2003-06-02 | 2023-04-05 | University of Massachusetts | Methods and compositions for controlling efficacy of rna silencing |
ES2357116T5 (es) | 2003-06-02 | 2021-09-03 | Univ Massachusetts | Métodos y composiciones para mejorar la eficacia y especificad de FNAi |
US20060241072A1 (en) | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
WO2005041857A2 (en) | 2003-10-07 | 2005-05-12 | Quark Biotech, Inc. | Bone morphogenetic protein (bmp) 2a and uses thereof |
WO2005103297A1 (en) | 2004-03-31 | 2005-11-03 | Georgetown University | METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
WO2005105829A2 (en) | 2004-04-30 | 2005-11-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
WO2005110464A2 (en) * | 2004-05-14 | 2005-11-24 | Oregon Health & Science University | Irx5 inhibition as treatment for hyperproliferative disorders |
JP2008501693A (ja) | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク. | 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物 |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
CA2576233C (en) | 2004-08-10 | 2016-03-15 | Alnylam Pharmaceuticals, Inc. | Conjugate comprising an antagomir and a ligand |
AP2007003921A0 (en) | 2004-08-16 | 2007-02-28 | Atugen Ag | Therapeutic uses of inhibitors of rtp801 |
DK1799269T3 (en) | 2004-09-28 | 2016-10-03 | Quark Pharmaceuticals Inc | Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases |
US20080261905A1 (en) | 2004-11-08 | 2008-10-23 | K.U. Leuven Research And Development | Modified Nucleosides for Rna Interference |
TW200639253A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
AU2006272808C1 (en) * | 2005-07-21 | 2010-10-21 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of the Rho-A gene and uses thereof |
CA2619876A1 (en) * | 2005-08-17 | 2007-02-22 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
UY30097A1 (es) * | 2006-01-20 | 2007-08-31 | Atugen Ag | Usos terapeuticos de inhibidores de rtp801 |
US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
EP1989307B1 (en) * | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
JP5646997B2 (ja) | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | 新規siRNA構造 |
-
2008
- 2008-09-04 JP JP2010527594A patent/JP5646997B2/ja not_active Expired - Fee Related
- 2008-09-04 CN CN200880110087.0A patent/CN101815521B/zh not_active Expired - Fee Related
- 2008-09-04 AU AU2008306455A patent/AU2008306455C1/en not_active Ceased
- 2008-09-04 KR KR1020107009512A patent/KR20100085951A/ko not_active Application Discontinuation
- 2008-09-04 US US12/733,998 patent/US8614309B2/en active Active
- 2008-09-04 CA CA2701845A patent/CA2701845A1/en not_active Abandoned
- 2008-09-04 WO PCT/IL2008/001197 patent/WO2009044392A2/en active Application Filing
- 2008-09-04 CN CN201210369167.6A patent/CN103898110A/zh active Pending
- 2008-09-04 EP EP08808012A patent/EP2231168A4/en not_active Withdrawn
- 2008-09-04 BR BRPI0817605A patent/BRPI0817605A2/pt not_active IP Right Cessation
- 2008-09-04 RU RU2010113514/10A patent/RU2487716C2/ru not_active IP Right Cessation
-
2012
- 2012-08-27 US US13/595,519 patent/US20130123334A1/en not_active Abandoned
-
2014
- 2014-06-18 JP JP2014125717A patent/JP2014210789A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011500003A5 (ja) | ||
RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
JP2013511990A5 (ja) | ||
JP2017079759A5 (ja) | ||
JP6426268B2 (ja) | 新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
JP2018519811A5 (ja) | ||
JP2013535212A5 (ja) | ||
JP2020058368A5 (ja) | ||
JP2020500929A5 (ja) | ||
JP2010505432A5 (ja) | ||
JP2014515351A5 (ja) | ||
JP2011500858A5 (ja) | ||
US11484546B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
JP6771387B2 (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー | |
JP2013537404A5 (ja) | ||
CN111448316A (zh) | 新的硫代亚磷酰胺 | |
WO2003004511A3 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
WO2008004610A1 (fr) | Méthode de traitement de maladie génétique provoquée par une mutation non sens | |
KR20150064065A (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna 를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
JP2020521491A5 (ja) | ||
JPWO2020146521A5 (ja) | ||
CN115819484A (zh) | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 | |
CN118355121A (zh) | 一种dsRNA、其制备方法及应用 | |
TW202340470A (zh) | 一種dsrna、其應用及製備方法 | |
KR20240116539A (ko) | LPA를 표적으로 하는 siRNA 및 접합체 |